Natulan (Procarbazine Hydrochloride)

Procarbazine is converted in the body to methylhydrazine, a compound that alkylates DNA. This alkylation disrupts DNA replication and transcription, leading to inhibition of tumor cell growth and ultimately causing cell death. The effect is non‑specific, affecting rapidly dividing cancer cells.

The dosage of Natulan is individualized by the treating physician based on the specific cancer protocol, patient weight, renal and hepatic function, and other clinical factors. Only a qualified prescriber can determine the appropriate dose and schedule.

Safety data for procarbazine hydrochloride in pregnancy and lactation are limited. Because it can cross the placenta and may be excreted in breast milk, it is generally contraindicated unless the potential benefit outweighs the risk. Consultation with a specialist is essential.

To request Natulan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Natulan (procarbazine) is an oral alkylating agent, whereas many alternatives such as cyclophosphamide are given intravenously. Procarbazine has a distinct metabolic pathway producing methylhydrazine, which may result in a different side‑effect profile, particularly a higher incidence of nausea and mild leukopenia.

Natulan should be stored at room temperature, below 25 °C, in its original packaging. It must be kept away from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Natulan is taken orally, usually in tablet form, as directed by the prescribing oncologist. The medication is swallowed with water, and dosing schedules are coordinated with other chemotherapy agents in the treatment protocol.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, secondary malignancies, and rare but potentially life‑threatening hypersensitivity reactions. Patients should be monitored closely for signs of infection, bleeding, or unexpected allergic symptoms.

Natulan should not be used by individuals with known hypersensitivity to procarbazine or any component of the formulation, by patients with severe bone‑marrow failure, or by those taking monoamine‑oxidase inhibitors. It is also contraindicated in pregnant women unless absolutely necessary.